Previous 10 | Next 10 |
Gainers: Inspira Technologies (NASDAQ:IINN) +92%. Ensysce Biosciences (NASDAQ:ENSC) +79%. Insignia (NASDAQ:ISIG) +44%. Hovnanian Enterprises (NASDAQ:HOVNP) +33%. American Virtual Cloud Technologies (NASDAQ:AVCT) +31%. Blue Star Foods Corp. (NASDAQ:BSFC) +16%. Hovnanian (NYSE:HO...
Gainers: Inspira Technologies (NASDAQ:IINN) +103%, Ensysce Biosciences (NASDAQ:ENSC) +53%, Jasper Therapeutics (NASDAQ:JSPR) +24%, Ambrx Biopharma (NYSE:AMAM) +17%, iSpecimen (NASDAQ:ISPC) +15%. Losers: Reata Pharmaceuticals (NASDAQ:RETA)...
IceCure Medical (NASDAQ:ICCM) priced an underwritten public offering of 3.31M shares at $3.45/share, pre-funded warrants to purchase up to 1.03M ordinary shares at $3.449/pre-funded warrant. This represents the per share public offering price for the ordinary shares less the $0.001/share exer...
IceCure Medical Ltd. Announces Pricing of $15 Million Underwritten Public Offering PR Newswire CAESAREA, Israel , Dec. 9, 2021 /PRNewswire/ -- IceCure Medical Ltd. (NASDAQ: ICCM) (TASE: ICCM) (the " Company " or " IceCure "), developer of minimally-in...
IceCure Medical's Interim Results of the ICE3 Clinical Trial for Early-Stage Breast Cancer Cryoablation featured at the 2021 Annual Meeting of the Radiological Society of North America PR Newswire CAESAREA, Israel , Dec. 2, 2021 /PRNewswire/ -- IceCure Medi...
Applied UV (NASDAQ:AUVI) +47%. Skylight Health Group (NASDAQ:SLHG) +27%. Ardelyx (NASDAQ:ARDX) +18%. IceCure Medical (NASDAQ:ICCM) +17%. Energy Focus (NASDAQ:EFOI) +17%. Ambarella (NASDAQ:AMBA) +15% on Q3 results VBI Vaccines (NASDAQ:VBIV) +14% wins FDA approval for Hepatitis B vacc...
IceCure Medical Announces Appointment of Merav Nir Dotan to Vice President Human Resources New executive appointment made commensurate with IceCure's growth related to the increased adoption of its flagship ProSense® Cryoablation System and development of next-generation of...
IceCure Medical (NASDAQ:ICCM): 9M GAAP EPS of $0.249. Revenue of $2.75M (+10.4% Y/Y) Press Release For further details see: IceCure Medical reports 9M results
IceCure Medical Reports Financial Results as of and for the first Nine Months of 2021 and Recent Corporate Developments PR Newswire CAESAREA, Israel , Nov. 23, 2021 /PRNewswire/ -- IceCure Medical Ltd. (NASDAQ: ICCM) (TASE: ICCM) ("IceCure" or the "Company"), dev...
IceCure Medical Announces New Independent Data Published in the Journal of Cancer Therapy Showing that Percutaneous Cryoablation Presents a Potential Substitute for Lumpectomy for Tumors <15mm using ProSense™ IceCure Medical Announces New Independent Data Published in ...
News, Short Squeeze, Breakout and More Instantly...
99.74% Recurrence Free Rate for Women with Breast Cancer Treated with IceCure's ProSense® Cryoablation System: Key Findings Delivered at 32nd Annual Meeting of the Japanese Breast Cancer Society PR Newswire Demand for minimally invasive breast cancer treatment was ove...
European Study Provides More Evidence Supporting IceCure's ProSense® is Safe & Effective Cryoablation Treatment for Metastatic and Recurrent Breast Cancer European Study Provides More Evidence Supporting IceCure's ProSense® is Safe & Effective Cryoablation Treatment fo...
U.S. Food and Drug Administration Grants Regulatory Clearance to IceCure for Next-Gen XSense™ Cryoablation System with CryoProbes PR Newswire CAESAREA, Israel , July 1, 2024 /PRNewswire/ -- IceCure Medical Ltd. (NASDAQ: ICCM) ("IceCure", "IceCure Medic...